Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$40.00
$40.00
$15.25
$43.00
$1.19B1.7710,339 shsN/A
Harrow, Inc. stock logo
HROW
Harrow
$31.60
-0.2%
$28.72
$20.85
$59.23
$1.16B0.41451,064 shs116,481 shs
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$3.17
-1.1%
$4.24
$2.19
$26.98
$336.92M0.672.24 million shs1.55 million shs
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$8.06
+4.7%
$6.71
$5.04
$16.74
$1.25B-1.011.29 million shs1.67 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
0.00%0.00%0.00%0.00%+2.41%
Harrow, Inc. stock logo
HROW
Harrow
+2.10%+3.57%+5.01%+34.84%+38.86%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
+8.11%+11.11%+5.96%-35.22%-84.87%
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
+10.79%+14.07%+9.22%+40.51%+43.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
N/AN/AN/AN/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
2.5914 of 5 stars
3.52.00.00.01.92.50.6
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
4.8433 of 5 stars
4.22.00.04.71.75.01.3
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
4.4203 of 5 stars
3.51.00.04.82.54.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
0.00
N/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
3.00
Buy$61.4094.33% Upside
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
2.41
Hold$18.60487.68% Upside
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
2.92
Moderate Buy$20.50154.37% Upside

Current Analyst Ratings Breakdown

Latest RCKT, CALT, HROW, and WVE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$18.00
6/17/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $5.00
6/12/2025
Harrow, Inc. stock logo
HROW
Harrow
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$62.00
6/11/2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$14.00
6/10/2025
Harrow, Inc. stock logo
HROW
Harrow
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
6/3/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$34.00 ➝ $11.00
5/30/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ In-Line$5.00
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$32.00 ➝ $9.00
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $8.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$1.60B0.74N/AN/A$1.06 per share37.74
Harrow, Inc. stock logo
HROW
Harrow
$212.86M5.45$0.14 per share226.78$1.95 per share16.20
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/A$5.08 per shareN/A
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$108.30M11.58N/AN/A$1.37 per share5.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/A
Harrow, Inc. stock logo
HROW
Harrow
-$17.48M-$0.56N/A78.99N/A-10.19%-25.01%-4.27%8/6/2025 (Estimated)
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$258.75M-$2.63N/AN/AN/AN/A-64.92%-56.13%8/4/2025 (Estimated)
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-$97.01M-$0.84N/AN/AN/AN/A-86.49%-37.20%8/14/2025 (Estimated)

Latest RCKT, CALT, HROW, and WVE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.01N/AN/AN/A$64.23 millionN/A
8/4/2025Q2 2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$0.57N/AN/AN/A$4.36 millionN/A
5/13/2025Q1 2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$0.58-$0.56+$0.02N/AN/AN/A
5/8/2025Q1 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million
5/8/2025Q1 2025
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 million
5/5/2025Q1 2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$0.59-$0.56+$0.03-$0.56$0.80 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
N/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
N/AN/AN/AN/AN/A
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/AN/A
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
9.44
2.69
2.59
Harrow, Inc. stock logo
HROW
Harrow
2.01
0.91
0.85
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
0.05
9.19
9.19
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
N/A
2.95
2.95

Institutional Ownership

CompanyInstitutional Ownership
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
2.83%
Harrow, Inc. stock logo
HROW
Harrow
72.76%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
98.39%
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
89.73%

Insider Ownership

CompanyInsider Ownership
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
2.20%
Harrow, Inc. stock logo
HROW
Harrow
15.16%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
24.76%
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
23.98%
CompanyEmployeesShares OutstandingFree FloatOptionable
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
18029.79 million29.14 millionOptionable
Harrow, Inc. stock logo
HROW
Harrow
18036.69 million31.12 millionOptionable
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
240106.79 million80.35 millionOptionable
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
240155.56 million118.26 millionOptionable

Recent News About These Companies

Brokerages Set WAVE Life Sciences Ltd. (NASDAQ:WVE) PT at $20.50
Wave Life Sciences: Speculative, But Promising
Wave Life Sciences Ltd. (WVE) - Yahoo Finance
Where WAVE Life Sciences Stands With Analysts

New MarketBeat Followers Over Time

Media Sentiment Over Time

Calliditas Therapeutics AB (publ) stock logo

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)
As of 07/9/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Harrow stock logo

Harrow NASDAQ:HROW

$31.59 -0.07 (-0.22%)
As of 03:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Rocket Pharmaceuticals stock logo

Rocket Pharmaceuticals NASDAQ:RCKT

$3.16 -0.04 (-1.09%)
As of 03:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

WAVE Life Sciences stock logo

WAVE Life Sciences NASDAQ:WVE

$8.04 +0.34 (+4.42%)
As of 03:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.